AT 9283

Drug Profile

AT 9283

Alternative Names: AT-9283

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals; Astex Therapeutics; Cancer Research UK; National Cancer Institute (Canada)
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Bcr-abl tyrosine kinase inhibitors; Janus kinase-2 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Medulloblastoma; Multiple myeloma; Myelofibrosis; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 09 Jan 2013 NCIC Clinical Trials Group completes a phase I trial in solid tumours and non-Hodgkin's lymphoma (second-line therapy or greater, monotherapy) in United Kingdom (NCT00443976)
  • 01 Dec 2012 Cancer Research UK completes a phase I trial in solid tumours (second-line therapy or greater, monotherapy, in children and adolescents) in United Kingdom (NCT00985868)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top